Sign in

    Albert Lowe • Craig-Hallum Capital Group LLC

    Albert Lowe is a Senior Biotechnology Equity Research Analyst at Craig-Hallum Capital Group LLC, specializing in biotechnology sector coverage, with a focus on companies such as Neurogene. He holds a TipRanks analyst success rate of 50%, reflecting the performance of his published investment calls. Lowe began his analyst career at Piper Sandler before joining Craig-Hallum in early 2024, and he holds a PhD in biomedical science from Albert Einstein College of Medicine as well as an undergraduate degree from UC San Diego. His professional credentials include senior-level healthcare research expertise and advanced academic training relevant to the life sciences and biotechnology industries.

    Albert Lowe's questions to Skye Bioscience Inc (SKYE) leadership

    Albert Lowe's questions to Skye Bioscience Inc (SKYE) leadership • Q2 2025

    Question

    Albert Lowe of Craig-Hallum Capital Group LLC asked if the 13-week follow-up period to track weight loss durability is still planned after the extension study and when that data might be released.

    Answer

    President, CEO & Director Punit Dhillon confirmed that the 13-week follow-up period will still occur after the 52-week extension study is complete. However, he noted that the data from this follow-up period would likely not be available until 2026.

    Ask Fintool Equity Research AI

    Albert Lowe's questions to Skye Bioscience Inc (SKYE) leadership • Q1 2025

    Question

    Albert Lowe of Craig-Hallum Capital Group LLC asked about the Data Safety Monitoring Committee (DMC) reviews and whether they would flag neuropsychiatric adverse events. He also sought clarification on the 8% weight loss expectation at 26 weeks and how to interpret data from the study's open-label extension.

    Answer

    Dr. Puneet Arora explained that the independent DMC, which includes two psychiatrists, meets quarterly to review all unblinded safety data, including neuropsychiatric events, and has raised no concerns. CEO Punit Dhillon reiterated the study is designed for an 8% placebo-adjusted weight loss but emphasized the primary goal is achieving a clear separation from placebo. He also noted that for the extension, key metrics will be collected at the start to account for any variability during the brief rollover period.

    Ask Fintool Equity Research AI